2025-11-06T11:23:26+00:00 2024-12-31 440160260 Forvis Mazars LLP 120 E Palmetto Park Road Suite 403 Boca Raton FL 33432 990 2024-01-01 521986675 Foundation for the National Institutes of Health Inc FOUN 3014025311 11400 Rockville Pike 600 North Bethesda MD 20852 Donald M Hill Chief Financial Officer 3014025311 2025-11-06 true true April Arnold P01559426 5612991820 2025-11-06 2024 2025-03-06 01:10:19Z Donald M Hill 11400 Rockville Pike 600 North Bethesda MD 20852 432563566 false X http://www.fnih.org X 1996 MD SEE SCHEDULE O 22 21 122 21 0 56092197 71750648 50000 50000 4762392 6516337 61199 190224 60965788 78507209 20270897 22714461 0 16465315 19849946 0 223254 32908531 34254511 69644743 76818918 -8678955 1688291 206113368 214056526 12576790 15192964 193536578 198863562 TO CREATE AND LEAD ALLIANCES AND PUBLIC-PRIVATE PARTNERSHIPS THAT ADVANCE BREAKTHROUGH BIOMEDICAL DISCOVERIES AND IMPROVE THE QUALITY OF PEOPLE'S LIVES false false 64210906 22057896 50000 SEE SCHEDULE O, PROGRAM ONE, RESEARCH PROGRAMS 1631357 656565 0 SEE SCHEDULE O, PROGRAM TWO, AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMS 65842263 true true false false false true false false false true true false false false true true true false false false true false false false true false false true true true false false false false false false false false false false true false false false true false false false false false true 48 0 true 122 true false false false false false true true false false false false false false false false false X 22 21 false false false false false false false true true false false false true true true true true true true true false false CA FL GA AL HI IL KS KY MD MA MI MN MS NH NJ NM NY OR PA RI SC TN UT VA AR WV WI X X Donald M Hill 3014356246 11400 Rockville Pike 600 North Bethesda MD 20852 Dr Julie L Gerberding Chief Executive Officer 40.0 X X 640273 0 49562 Charles A Reinhart III Board Member 2.0 X 0 0 0 Dr Charles A Sanders Board Member 0.5 X 0 0 0 Dr Edison T Liu Board Member 0.5 X 0 0 0 Dr Elias Zerhouni Board Member 0.5 X 0 0 0 Dr Ellen V Sigal Board Member 0.5 X 0 0 0 Dr Freda Lewis-Hall Board Member 0.5 X 0 0 0 Dr Gilbert S Omenn Board Member 0.5 X 0 0 0 Dr Jay Bradner Board Member 0.5 X 0 0 0 Dr Judy Lansing Kovler Board Member 0.5 X 0 0 0 Dr Paul Stoffels Board Member 0.5 X 0 0 0 Dr Ronald L Krall Board Member 0.5 X 0 0 0 Dr Solomon H Snyder Vice-Chairman 0.5 X 0 0 0 Dr Steven M Paul Chairman 2.0 X 0 0 0 James Weiss Board Member 0.5 X 0 0 0 Mr Fred Seigel Board Member 0.5 X 0 0 0 Mr James Down Board Member 0.5 X 0 0 0 Mr Perry Steiner Board Member 2.0 X 0 0 0 Mr Russell W Steenberg Board Member 0.5 X 0 0 0 Mrs William McCormick Blair Jr Secretary 1.0 X 0 0 0 Ms Julie Bell Lindsay Treasurer 2.0 X 0 0 0 Ms Nina Kjellson Board Member 0.5 X 0 0 0 David Carmel Senior Vice President, Chief Growth and Innovation Officer 40.0 X 451716 0 49562 Donald Hill Senior Vice President, Chief Financial Officer 40.0 X 336184 0 49267 Joseph Menetski Senior Vice President, Chief Translational Science Officer 40.0 X 388734 0 46512 Kevin Klock Senior Vice President, Chief Operating Officer and General Counsel 40.0 X 321510 0 45977 Love Collins Vice President, Advancement 40.0 X 182550 0 24199 Michael Santos Senior Vice President, Chief Population Health Science Officer 40.0 X 392350 0 36416 Catherine Master Vice President, Deputy General Counsel 40.0 X 238984 0 41018 Courtney Silverthorn Vice President, Strategic Alliances and Innovation 40.0 X 261804 0 29966 Eva Coyne Vice President -Controller 40.0 X 245164 0 38777 Stacey Adam Vice President, Science Partnerships 40.0 X 281317 0 31193 Steven Hoffmann Vice President, Science Partnerships 40.0 X 264766 0 40305 4005352 0 482754 74 false true false Dana-Farber Cancer Institute 450 Brookline Avenue Boston MA 02215 Transitional Science Research Collaboration 1761570 SWOG CTI 24 Frank Lloyd Wright Drive PO Box 483 Ann Arbor MI 48105 Clinical Trial for Lung Map Project 1500260 The Regents of the University of CaliforniaSD 9500 Gilman Drive MC 0009 La Jolla CA 920930955 NIMBLE and AMP CMD Research Collaboration 1406374 Ruder Finn Inc 425 E 53rd St New York NY 10022 Professional Services 1299020 Discovery Life Sciences LLC 900 Hudson Way Huntsville AL 35806 AMP PD Project Research Collaboration 1192389 46 361000 1250000 70139648 3568243 71750648 Administrative Revenue 900099 50000 50000 0 0 0 0 50000 5005462 5005462 0 0 354996860 353485985 1510875 0 1510875 1510875 760596 361000 570372 190224 190224 0 0 0 0 0 78507209 50000 0 6706561 21813761 21813761 900700 900700 3014812 878711 2136101 0 12431054 8511158 3884270 35626 1045925 617456 412395 16074 2250867 1447651 758376 44840 1107288 628942 460317 18029 266563 266563 125628 125628 236721 236721 4029577 3308966 712172 8439 41120 36558 4353 209 60492 30533 29834 125 271180 116972 138133 16075 737279 181564 555715 3110676 2690383 340593 79700 571210 502890 67876 444 233505 233505 242768 131491 111277 Program Contracts 23726622 23726622 Recruiting 184466 97138 87328 Bad Debt Expense 100000 100000 Equipment Rental and Maintenance 74547 6762 67785 242157 114005 124459 3693 76818918 65842263 10753401 223254 3466426 33349260 37968576 42017805 44187096 0 0 0 0 366589 503799 3281124 1921669 1470643 1359455 120900511 120117237 0 0 8008560 6453937 206113368 214056526 4105123 7931677 408334 0 0 0 8063333 7261287 12576790 15192964 X 32672601 38503375 160863977 160360187 193536578 198863562 206113368 214056526 X 1688291 2983892 654801 X false true true true true X 98343956 105993785 68998263 56092197 71750648 401178849 0 0 98343956 105993785 68998263 56092197 71750648 401178849 119793612 281385237 1722957 1346882 2204173 4421167 5005462 14700641 0 0 0 0 0 760596 760596 416640086 200000 0.67537 0.66084 X Schedule A, Part II, Line 10 Other Income DESCRIPTION - FUNDRAISING REVENUE, COLUMN A - , COLUMN B - , COLUMN C - , COLUMN D - , COLUMN E - 760596.0, COLUMN F - 760596.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 2 0 280087 0 735196 0 606662 0 true true 22940299 4517789 594281 148712 27903657 20829215 1847034 523194 259144 22940299 24511134 -85775 -788802 2807342 20829215 20878035 3154350 544664 65915 24511134 14897505 5648998 419982 88450 20878035 0.7144 0.2856 0.0 false false 1869159 850569 1018590 1411965 1071100 340865 1359455 Federal Income Taxes Charitable Gift Annuity 103001 Operating Lease Liability 7158286 7261287 X 82158766 2983892 334014 0 3317906 78840860 236721 -570372 -333651 78507209 76831782 334014 -84429 249585 76582197 236721 0 236721 76818918 Schedule D, Part V, Line 4 Intended uses of endowment funds The Foundation has one endowment that is funded by multiple donors to seed new discoveries and/or be available to respond to epidemics and Foundation's unanticipated needs. The Foundation's other endowments consist of individual donor-restricted endowment funds established for a variety of purpose. (e.g. variety of research and educational initiatives at the Foundation for the NIH, Inc). Net assets associated with endowment funds are classified and reported based on the existence or absence or donor-imposed restrictions. Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote The Foundation is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code; accordingly, the accompanying financial statements do not reflect a provision or liability for federal and state income taxes. The Foundation has determined that it does not have any material unrecognized tax benefits or obligations as of December 31, 2024 and 2023. Schedule D, Part XI, Line 4(b) Other revenues in form 990 not in audited financial statements Fundraising Event Expenses - -570372 Schedule D, Part XII, Line 2(d) Other expenses in audited financial statements not in form 990 Fundraising Event Expenses - 570372 Refund of Prior Year Grants - -654801 East Asia and the Pacific 0 0 Program Services RESEARCH 155551 Sub-Saharan Africa 0 0 Program Services EDUCATION & TRAINING 1034777 Europe (Including Iceland and Greenland) 0 0 Program Services RESEARCH 1542714 0 0 0 0 0 0 2733042 0 2733042 false false false false false false Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; SUB-SAHARAN AFRICA-Accrual FNIH Award Ceremony 1121596 361000 760596 48824 521548 0 0 0 0 1121596 361000 760596 48824 521548 570372 190224 true NIH NIA 9000 Rockville Pike Bethesda MD 20892 520858115 170(C)(1) GOVT UNIT 18000 Research NIHNCI 9000 Rockville Pike Bethesda MD 20892 520858115 170(C)(1) GOVT UNIT 3724778 Research NIHNIAID 9000 Rockville Pike Bethesda MD 20892 520858115 170(C)(1) GOVT UNIT 1834488 Research NIHNIAMS 9000 Rockville Pike Bethesda MD 20892 520858115 170(C)(1) GOVT UNIT 8700000 Research NIHNINDS 9000 Rockville Pike Bethesda MD 20892 520858115 170(C)(1) GOVT UNIT 614100 Research NIH NHLBI 9000 Rockville Pike Bethesda MD 20892 520858115 170(C)(1) GOVT UNIT 512204 Research NIHOD 9000 Rockville Pike Bethesda MD 20892 520858115 170(C)(1) GOVT UNIT 249500 Research NIH NIMH 9000 Rockville Pike Bethesda MD 20892 520858115 170(C)(1) GOVT UNIT 2614331 Research NIHNEI 9000 Rockville Pike Bethesda MD 20892 520858115 170(C)(1) GOVT UNIT 31500 Research Research Triangle Institute PO Box 900002 Raleigh NC 27675 560686338 501(c)(3) 836038 Research University of Alabama at Birmingham Dept of Pediatric Admin Lowder Bl 1600 7th Avenue South Birmingham AL 352331711 636001138 501(c)(3) 304475 Research Thomas Jefferson University 125 South 9th Street 2nd Floor Sheridan Building Philadelphia PA 19107 231352651 501(c)(3) 736764 Research University of North Carolina Chapel Hill 104 Airport Drive Suite 2200 Campus Box 1350 Chapel Hill NC 27599 800543561 501(c)(3) 215635 Research University of Virginia PO Box 400195 Charlottesville VA 229044195 546001796 501(c)(3) 119034 Research University of Colorado Denver PO Box 910238 Denver CO 80291 846000555 501(c)(3) 15091 Research Duke University - Human Vaccine Institiute 200 West Main Street Suite 820 Erwin Square Plaza Durham NC 27705 560532129 501(c)(3) 79647 Research Fred Hutchinson Cancer Research Center 1100 Fairview Ave N Seattle WA 98109 237156071 501(c)(3) 562536 Research Trustees of Boston University 85 East Newton Street M-921 Boston MA 02118 042103547 501(c)(3) 231516 Research Friends of Cancer Research 1800 M Street NW Suite 1050 South Washington DC 20036 521983273 501(c)(3) 138296 Research Leidos Biomedical Research Inc 1050 Boyles Street Frederick MD 21702 330653185 127477 Research The Trustees of Columbia University PO Box 29789 General Post Office New York NY 100879789 135598093 501(c)(3) 148351 RESEARCH 20 1 Awards 26 900700 Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds Program and grants management staff invest considerable effort in providing scientific, administrative, and fiscal oversight for FNIH grants. Scientific and technical progress is monitored through semi-annual and annual reports from the grantees as well as through direct contact with investigators both by teleconference and site visits, and follow up to progress reports and site visits where scientific questions or administrative issues are identified. Scientific report submissions cover a wide range of items including individual objectives and overall progress review, milestone achievement, project plan update, and any other significant changes. Financial reporting is required annually for all of the grantees, and semi-annually for institutions that require additional oversight, such as for-profit institutions. Due diligence procedures, such as FNIH compliance with the USA Patriot Act and IRS requirements on expenditure responsibilities, have been incorporated into the reporting process to ensure that the grantees are complying with grant, legal, financial, and regulatory requirements. FELLOWS SELECTED FOR FOUNDATION FELLOWSHIPS ARE SELECTED THROUGH NATIONWIDE AND INTERNATIONAL COMPETITIONS. X X X X X false false false false false false false false false Dr Julie L Gerberding Chief Executive Officer 532225 0 105000 0 3048 0 27600 0 21962 0 689835 0 0 0 Donald Hill Senior Vice President, Chief Financial Officer 314600 0 20000 0 1584 0 27305 0 21962 0 385451 0 0 0 David Carmel Senior Vice President, Chief Growth and Innovation Officer 428300 0 20000 0 3416 0 27600 0 21962 0 501278 0 0 0 Joseph Menetski Senior Vice President, Chief Translational Science Officer 367150 0 20000 0 1584 0 27600 0 18912 0 435246 0 0 0 Kevin Klock Senior Vice President, Chief Operating Officer and General Counsel 301150 0 20000 0 360 0 26065 0 19912 0 367487 0 0 0 Michael Santos Senior Vice President, Chief Population Health Science Officer 371990 0 20000 0 360 0 27600 0 8816 0 428766 0 0 0 Love Collins Vice President, Advancement 179460 0 0 0 3090 0 14554 0 9645 0 206749 0 0 0 Courtney Silverthorn Vice President, Strategic Alliances and Innovation 249769 0 11800 0 235 0 20950 0 9016 0 291770 0 0 0 Eva Coyne Vice President -Controller 235650 0 9000 0 514 0 19865 0 18912 0 283941 0 0 0 Stacey Adam Vice President, Science Partnerships 266460 0 14500 0 357 0 22477 0 8716 0 312510 0 0 0 Steven Hoffmann Vice President, Science Partnerships 250750 0 12500 0 1516 0 21393 0 18912 0 305071 0 0 0 Catherine Master Vice President, Deputy General Counsel 228709 0 7500 0 2775 0 19406 0 21612 0 280002 0 0 0 1 40151 Market value 12 3478095 Market value X Computers 1 49997 Market value 0 false false false Schedule M, Part I Explanations of reporting method for number of contributions Securities - Publicly traded - Number of Contributions Other - Computers Number of Contributions Drugs and medical supplies - Number of Contributions Form 990, Part I, Line 1 Brief Mission To create and lead alliances and public-private partnerships that advance breakthrough biomedical discoveries and improve the quality of people's lives scientists at the National Institutes of Health (NIH) with their counterparts in life sciences companies, academia, patient organizations, foundations, and regulatory agencies (including the Food and Drug Administration and European Medicines Agency). Through team science, the FNIH solves complex health challenges and accelerates breakthroughs for patients, regardless of who they are or what health threats they face. The FNIH contributes to the development of new therapies, diagnostics, and potential cures; advances global health; and helps train the next generations of scientists. Established by Congress in 1990 to support the mission of the NIH, the FNIH is a not-for-profit 501(c)(3) charitable organization. Form 990, Part III, Line 4a Program Service Description PROGRAM ONE - RESEARCH PROGRAMS - ACCELERATING MEDICINES PARTNERSHIP PROGRAM The FNIH manages the Accelerating Medicines Partnership (AMP) program with the interests of the collective scientific and medical research communities in mind. Its mission is to improve understanding of disease pathways, facilitate better selection of targets for treatment, and identify platforms and processes to accelerate new and effective therapies to patients. All AMP projects operate under the broad principle of delivering pre-competitive advancements to the research and medical fields and enabling the broadest possible access and use of AMP research discoveries. A critical component of each public-private partnership in the AMP program is an agreement among partners to make data and analyses arising from the collaboration publicly accessible to benefit the broader biomedical community. Individual AMP projects frequently establish public portals to rapidly disseminate data from their research efforts, and AMP-funded publications are required to be made available publicly within specific timeframes. At the center of the AMP program is a common goal of accelerating new and effective therapies to patients. AMP projects work towards this goal by identifying clinically relevant disease targets, improving identification of patients most likely to respond to a particular treatment, and safely reducing the development timelines for life-saving therapies and improvements in patient outcomes. The AMP program celebrated its 10-year anniversary in 2024 with a two-day symposium spotlighting the wide-ranging impact of the initiative. BIOMARKERS CONSORTIUM The Biomarkers Consortium (BC) creates and leads cross-sector efforts that validate and qualify biomarkers and other tools to accelerate better decision making for the development of new therapeutics and health technologies. It convenes government, industry, patients and patient advocacy groups, and not-for-profit organizations to address one of the most pressing needs in the diagnosis and treatment of disease: the development and the seeking of regulatory approval for disease biomarkers and surrogate endpoints. The BC is helping facilitate, catalyze, and support a new era of precision medicine by advancing biomarker science to enable earlier interventions, personalized treatments, and better outcomes in disease prevention, detection, diagnosis, and therapy. GENECONVENE GLOBAL COLLABORATIVE The GeneConvene Global Collaborative continues to advance best practices and support informed decision-making on the scientific, regulatory, and policy questions raised by the development of genetic biocontrol technologies to control the spread of malaria and other mosquito-borne diseases. GeneConvene convened in 2024 a working group of developers preparing for field trials to assess technologies for entomological monitoring and surveillance, hosting a webinar and meeting on environmental monitoring, and leading a Gene Drive Research Forum discussion of the opportunities for ecological modeling to further contribute to safety assessments. Through the African Genetic Biocontrol Consortium, the program also conducted two workshops for scientists and science communicators to build relationships and skills. GeneConvene also strengthened biosafety regulatory capacity through a training conducted with the African Union Development Agency-NEPAD and sponsored a course for 50 faculty and PhD-level scientists from African institutions on genome editing. RESEARCH PROGRAMS FOR ACCELERATING NEW THERAPIES RESEARCHING COVID TO ENHANCE RECOVERY-TREATING LONG COVID (RECOVER-TLC) RECOVER-TLC is a partnership between the NIH's National Institute of Allergy and Infectious Diseases and the FNIH, with the overarching goal to launch additional Long COVID clinical trials with promising agents. Therapeutic submissions were submitted to the online portal in 2024, and a process was created to enable uniform assessment of all submitted agents. These efforts initiated early working group formation, with the Antiviral Working Group conducting initial agent review by the end of 2024. NEW AMP PROJECTS AMP AMYOTROPHIC LATERAL SCLEROSIS (ALS) AMP ALS was launched in 2024 to expedite the identification of biomarkers and clinical outcome assessments that would allow earlier diagnosis and accelerated drug development for ALS, a progressive and ultimately fatal neurological disease. The project will create the largest data source for ALS research. AMP PARKINSON'S DISEASE AND RELATED DISORDERS (PDRD) AMP PDRD, launched in 2024, seeks to employ a data-driven approach to identify and validate biomarkers distinguishing Parkinson's disease from related diseases, with an overarching goal to enhance the success of clinical trials and ultimately broaden treatment options for individuals affected by these conditions. BIOMARKERS CONSORTIUM RESEARCH PROJECTS EARLY DETECTION OF ALZHEIMER'S DISEASE: PLASMA A Results of a Plasma A project study on early diagnosis of Alzheimer's disease were published last year. This head-to-head evaluation and cross-platform validation of biomarkers that most accurately detect amyloid plaques and other Alzheimer's-related pathologies revealed that the performance of some blood plasma tests were as good as cerebrospinal fluid tests. This finding suggested that simple blood tests could replace invasive spinal taps or costly brain scans for many patients. The study confirmed that blood tests are an accessible, less invasive, and highly accurate method of detecting amyloid plaques. The study offered further confirmation that blood tests measuring levels of the protein p-tau217 are the most accurate in determining the presence and amount of amyloid plaques. Alzheimer's blood tests could speed future drug development by helping researchers select the optimal participants for clinical trials. NEUROFILAMENT AS A BLOOD-BASED BIOMARKER OF NEURODEGENERATION IN FAMILIAL FTD The earliest stages of frontotemporal dementia (FTD) are hard to detect until the disease has progressed and damage is permanent. This project seeks to identify reliable blood tests to detect FTD and give access to disease-modifying clinical trials. The FDA accepted a Letter of Intent to qualify neurofilament (a key protein component of neurons) as a biological indicator of FTD in April 2024. This biomarker qualification initiative is crucial for improving the ability to identify individuals at high risk of progressing to clinical disease, as well as for advancing the development of a formal biomarker qualification plan to support future studies on neurofilament and its role in FTD. This progress lays the groundwork for enhancing early detection and accelerating research efforts in neurodegenerative diseases. IDENTIFYING RISK OF PROGRESSION TO MULTIPLE MYELOMA: MMYERISK Multiple myeloma, a cancer of plasma cells, is almost always preceded by asymptomatic, pre-malignant conditions, including monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Although these precursor conditions are common, most patients do not progress to multiple myeloma. MMyeRisk, launched in 2024, seeks to identify which patients are likely to progress and identify those likely to benefit from early therapeutic intervention. The project team expects to achieve these aims through validation of blood-based genomic methods to define tumor and immune biomarkers. EVALUATING IMMUNOTHERAPY TREATMENT RESPONSE: IRELATE Despite the potential of immunotherapy, only a minority of patients respond to treatment. As effective immunotherapy treatments enhance T-cell infiltration and activation, understanding T-cell behavior is paramount for developing successful treatment strategies. Biopsies are used to assess T-cell states, but they are invasive and may not accurately reflect tumor burden. Positron emission tomography (PET) imaging holds promise as a non-invasive, comprehensive means for evaluating T-cell activity. The iRelate project aims to assess T-cell presence and activation state using two PET ligands in clinical development. Using both PET tracers will enable characterization of tracer uptake in tumor tissue and T cell-rich organs and is expected to provide information on unique and additive capacities of these tracers. This work is intended to serve as a foundation for defining potential context of use for PET biomarkers and to support the development and selection of successful immunotherapy treatment strategies. Form 990, Part III, Line 4a Program Service Description RESEARCH PROGRAMS FOR ADVANCING GLOBAL HEALTH A-PLUS: ANTIBIOTIC PROVES COST EFFECTIVE IN REDUCING MATERNAL INFECTIONS A 2023 international trial, supported in part by the FNIH, revealed that one dose of the oral antibiotic azithromycin during labor can greatly reduce maternal sepsis or death in low- and middle-income countries. For this work, the research team won top honors from the Clinical Research Forum in 2024. Two analyses published in 2024 using data from that trial, the Azithromycin Prevention in Labor Use Study (A-PLUS), assessed possible additional benefits of this strategy to prevent infections, which account for approximately 11% of maternal deaths worldwide. One of the two recent studies showed that any maternal infection, including sepsis, abscesses, and wound infections, occurred 29% less often when the drug was administered during labor. The second study, which modeled the benefits and costs of intrapartum azithromycin, showed a reduction in hospital readmissions, unplanned clinical visits, and use of additional antibiotics. Using the average health-care costs across the study's eight clinical sites, the savings was estimated at $32,661 per 100,000 pregnancies. STRENGTHENING THE PATIENT VOICE Patients are at the heart of the FNIH mission, and their voices are incorporated into our research programs. People with lived experiences, patient advocacy groups, and care providers are vital to our work, helping to ensure that our programs look holistically at the impact our research will have on health and well-being. The FNIH's patient engagement strategy - including the Patient Ambassadors and Patient Engagement Council - reflects our commitment to ensuring patient voices guide our work. Their insights are essential to shaping impactful, forward-looking research programs. Form 990, Part III, Line 4b Program Service Description PROGRAM TWO - AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMS - POWERING SCIENCE: 2024 FNIH AWARDS THE LURIE PRIZE IN BIOMEDICAL SCIENCES The Lurie Prize recognized outstanding achievement by promising scientists aged 52 years old or younger. The award included a $100,000 honorarium. PAUL-GALLIN TRAILBLAZER PRIZE FOR PHYSICIAN-SCIENTISTS The Paul-Gallin Trailblazer Prize recognizes the outstanding contributions of early- to mid-career physician-scientists whose research translates basic discoveries into novel approaches for diagnosing, preventing, treating, or curing disease and disability. The award includes a $100,000 honorarium. CHARLES A. SANDERS, MD, PARTNERSHIP AWARD We recognize our partners and their contributions through the annual Charles A. Sanders, MD, Partnership Award. This prize recognizes persons and/or organizations that have made significant contributions to our work in creating, implementing, and nurturing public-private partnerships that build bridges to breakthroughs in improved therapeutics, diagnostics, and potential cures. KOVLER PRIZE FOR TRUST IN LIFE SCIENCE JOURNALISM The Kovler Prize, which debuted in 2024 and carries a $25,000 honorarium, recognizes individual reporters who make complex health- and science-related topics digestible for the public. EVENTS AND EDUCATION In collaboration with the NIH and generous donors and partners, the FNIH manages training initiatives that offer educational opportunities to science students, ranging from high school to post-doctoral scholars, crossing boundaries and cultures. They learn through intensive training, collaborative engagement, mentoring, and hands-on research. Legacy funds from individual benefactors and foundations help move scientific achievement farther, faster, and give hope to future patients. Individual programs provide financial support, mentoring, and recognition to promising young scientists. Here is a just a sample of how the FNIH and its supporters power science: - The Deeda Blair Research Initiative for Disorders of the Brain awarded in 2024 three promising early-career physician-scientists with bold approaches to address mental illness. Each awardee received $200,000. This initiative was established by Mrs. William McCormick Blair, Jr., a member of the FNIH Board of Directors. - The Medical Research Scholars Program is a one-year intensive training program on the NIH campus offering medical, dental, and veterinary students opportunities to become engaged in research early in their careers. The FNIH has supported a total of 572 scholars since the program was established. - The FNIH promotes emerging research from up-and-coming scientists through annual lectures co-sponsored by the National Eye Institute, the National Institute of Neurological Disorders and Stroke, the National Institute of Allergy and Infectious Diseases, the National Center for Complementary and Integrative Health, and elsewhere. - For a complete list of all the ways the FNIH is powering science, go to the FNIH website. Form 990, Part VI, Line 15a & 15b - Process to Establish Compensation The Compensation Committee of the Board reviewed and concurred with the CEO's decisions establishing and adjusting the senior executive team's annual salaries and related compensation decisions. The Compensation Committee also approved the compensation level of the CEO and related compensation decisions. This process is undertaken annually. Form 990, Part VI, Line 1a Delegate broad authority to a committee The Board has an Executive Committee, which can make decisions on behalf of the Board (with some exceptions) between board meetings. Form 990, Part VI, Line 11b Review of form 990 by governing body The Form 990 is prepared and reviewed by an independent accounting firm. Prior to the submission of the Foundation for NIH's Form 990 to the Internal Revenue Service, each voting member of the board of directors shall be provided with a copy of the draft Form 990 as approved by the Chief Financial Officer. Form 990, Part VI, Line 12c Conflict of interest policy Directors, officers and employees are required to annually sign a statement which affirms that they have: - Received a copy of the conflict of interest policy - Read, understood and agreed to comply with the policy - Received and reviewed a listing of corporate and foundation donors, contractors, vendors, grantees, principal investigators and financial institutions with whom the FNIH has a current relationship - No actual or apparent conflicts of interest other than those disclosed in the statement. They must also make certain notifications in particular circumstances. The conflict of interest policy also has mechanisms for handling such conflicts. Form 990, Part VI, Line 19 Required documents available to the public All such documents are available upon request. In addition, the governing documents and financial statements are available on the FNIH website. Form 990, Part X, Column (B) Cash & Investments Approximately $122 Million of FNIH's Cash and Investments are invested in high quality short-term fixed income securities which are committed to FNIH's restricted assets. Form 990, Part XI, Line 9 Other changes in net assets or fund balances Refund of Prior Year Grants - 654801; Total - 654801; Health Data Access Authority LLC 11400 Rockville Pike Suite 600 North Bethesda MD 20852 333779122 To further the exempt purposes of the Foundation for the National Institutes of Health MD 0 0 Foundation for the National Institutes of Health Inc